DK2711017T3 - Immunitets-inducerende middel - Google Patents

Immunitets-inducerende middel Download PDF

Info

Publication number
DK2711017T3
DK2711017T3 DK12784927.1T DK12784927T DK2711017T3 DK 2711017 T3 DK2711017 T3 DK 2711017T3 DK 12784927 T DK12784927 T DK 12784927T DK 2711017 T3 DK2711017 T3 DK 2711017T3
Authority
DK
Denmark
Prior art keywords
arg
glu
ala
leu
asp
Prior art date
Application number
DK12784927.1T
Other languages
English (en)
Inventor
Akira Kurihara
Fumiyoshi Okano
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of DK2711017T3 publication Critical patent/DK2711017T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (12)

1. Immunitets-inducerende middel til anvendelse i en fremgangsmåde til medicinsk eller veterinær behandling, hvor det immunitets-inducerende middel omfatter som et aktivstof(fer) mindst et polypeptid med en immunitetsinducerende aktivitet udvalgt fra polypeptidet (a) og (b) nedenfor og/eller en rekombinant vektor(er), som omfatter et polynukleotid(er), der koder det mindst ene polypeptid, hvor den rekombinante vektor(er) kan eksprimere polypeptidet (polypeptiderne) in vivo\ (a) et polypeptid med en aminosyresekvens af en af SEQ ID NR:4, 2, 8, 10 og 12; (b) et polypeptid med en sekvensidentitet på ikke mindre end 85 % med polypeptid (a).
2. Immunitets-inducerende middel til anvendelse ifølge krav 1, hvor polypeptidet, som har en immunitets-inducerende aktivitet, er et polypeptid, som har aminosyresekvensen af SEQ ID NO:4, 2, 8, 10 eller 12.
3. Immunitets-inducerende middel til anvendelse ifølge krav 1 eller 2, hvor fremgangsmåden omfatter indgivelse til en patient af (i) polypeptidet eller vektoren, (ii) en cytotoksisk T-celle, som selektivt binder et kompleks, som omfatter det mindst ene polypeptid, der er inkorporeret i et MHC-molekyle, og/eller (iii) en antigen-præsenterende celle, som repræsenterer på sin overflade et kompleks, der omfatter det mindst ene polypeptid, der er inkorporeret i et MHC-molekyle.
4. Immunitets-inducerende middel til anvendelse ifølge et af kravene 1-3, som er til anvendelse ved behandling eller forebyggelse af en kræftform (kræftformer).
5. Immunitets-inducerende middel til anvendelse ifølge krav 4, hvor kræftformen (kræftformerne) er en kræftform (kræftformerne), der eksprimerer KAT-NAL 1.
6. Immunitets-inducerende middel til anvendelse ifølge krav 4 eller 5, hvor kræftformen (kræftformerne) er brystkræft, hjernetumor, perianalt adenokar-cinom, neuroblastom, mastocytom, leverkræft, prostatakræft, lungekræft, skjoldbruskkirtelkræft og/eller leukæmi.
7. Immunitets-inducerende middel til anvendelse ifølge et af kravene 1 til 6, yderligere omfattende en immunoenhancer.
8. Immunitets-inducerende middel til anvendelse ifølge krav 7, hvor immuno-enhanceren er mindst en udvalgt fra gruppen bestående af Freund's inkom-plete adjuvans; Montanid; poly-l:C og derivater deraf; CpG-oligonukleotider; interleukin-12; interleukin-18; interferon-a; interferon-β; interferon-ω; interfe-ron-γ; og Flt3-ligand.
9. In wYro-fremgangsmåde til fremstilling af en antigen-præsenterende celle, hvilken fremgangsmåde omfatter at bringe den antigen-præsenterende celle i kontakt med det mindst ene polypeptid udvalgt fra: (a) et polypeptid med en aminosyresekvens af en af SEQ ID NR:4, 2, 8, 10 og 12; og (b) et polypeptid med en sekvensidentitet på ikke mindre end 85 % med polypeptid (a).
10. In v/Yro-fremgangsmåde til fremstilling af en cytotoksisk T-celle, hvilken fremgangsmåde omfatter: at samdyrke en antigen-præsenterende celle, som er fremstillet i henhold til fremgangsmåden ifølge krav 9, med mindst en T-celle, og gøre det muligt for den mindst ene T-celle at proliferere
11.
In wYro-fremgangsmåde ifølge krav 10, hvor en antigen-præsenterende celle: T-celleforholdet på 1:1 til 1:100 anvendes, eventuelt hvor samdyrkningen udføres i nærvær af IL-2, IL-6, IL-7 og/eller IL-12.
DK12784927.1T 2011-05-19 2012-05-18 Immunitets-inducerende middel DK2711017T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011112181 2011-05-19
PCT/JP2012/062750 WO2012157737A1 (ja) 2011-05-19 2012-05-18 免疫誘導剤

Publications (1)

Publication Number Publication Date
DK2711017T3 true DK2711017T3 (da) 2016-11-07

Family

ID=47177051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12784927.1T DK2711017T3 (da) 2011-05-19 2012-05-18 Immunitets-inducerende middel

Country Status (13)

Country Link
US (2) US20140120059A1 (da)
EP (1) EP2711017B1 (da)
JP (1) JP5954174B2 (da)
KR (1) KR101949186B1 (da)
CN (1) CN103547284B (da)
AU (1) AU2012256757B2 (da)
BR (1) BR112013029704A2 (da)
CA (1) CA2836568C (da)
DK (1) DK2711017T3 (da)
ES (1) ES2595161T3 (da)
PL (1) PL2711017T3 (da)
RU (1) RU2614386C2 (da)
WO (1) WO2012157737A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105296603A (zh) * 2014-07-28 2016-02-03 广州君赫生物科技有限公司 一种检测男性不育症Katnal1基因突变位点的试剂盒及其PCR扩增方法
PT3290048T (pt) * 2015-04-30 2020-11-19 Toray Industries Agente indutor de imunidade
WO2017026389A1 (ja) * 2015-08-10 2017-02-16 東レ株式会社 免疫誘導剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US153312A (en) * 1874-07-21 Improvement in handcuffs
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6410687B1 (en) * 1998-04-14 2002-06-25 The Regents Of The University Of California Polypeptides for the detection of microtubule depolymerization inhibitors
EP1242443A4 (en) * 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
JP2003532419A (ja) 2000-05-05 2003-11-05 インサイト・ゲノミックス・インコーポレイテッド 細胞骨格結合タンパク質
WO2002081518A2 (en) * 2001-02-21 2002-10-17 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
US20040078804A1 (en) 2001-05-03 2004-04-22 Henry Yue Cytoskeleton-associated proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
JP2004008216A (ja) 2002-03-22 2004-01-15 Research Association For Biotechnology 新規な全長ｃＤＮＡ
BRPI0507958A (pt) * 2004-02-23 2007-07-17 Novartis Ag biomarcadores
PL2837383T3 (pl) * 2008-08-05 2017-07-31 Toray Industries, Inc. Środek indukujący odporność
HUE037593T2 (hu) * 2009-09-03 2018-09-28 Toray Industries Immunitásindukáló
JP2011092100A (ja) * 2009-10-29 2011-05-12 Dna Chip Research Inc 生理的状態変化と生理的状態に変化を与える要因の効果を評価する遺伝子マーカー、評価方法、評価システム、及びコンピュータプログラム

Also Published As

Publication number Publication date
ES2595161T3 (es) 2016-12-28
KR20140034224A (ko) 2014-03-19
EP2711017A4 (en) 2014-11-05
US10463725B2 (en) 2019-11-05
AU2012256757A1 (en) 2014-01-09
CN103547284B (zh) 2015-11-25
KR101949186B1 (ko) 2019-02-18
EP2711017B1 (en) 2016-08-03
US20140120059A1 (en) 2014-05-01
CA2836568C (en) 2020-07-21
EP2711017A1 (en) 2014-03-26
PL2711017T3 (pl) 2017-01-31
CA2836568A1 (en) 2012-11-22
WO2012157737A1 (ja) 2012-11-22
US20160030540A1 (en) 2016-02-04
BR112013029704A2 (pt) 2017-08-29
JP5954174B2 (ja) 2016-07-20
RU2013156368A (ru) 2015-06-27
CN103547284A (zh) 2014-01-29
JPWO2012157737A1 (ja) 2014-07-31
AU2012256757B2 (en) 2017-06-15
RU2614386C2 (ru) 2017-03-27

Similar Documents

Publication Publication Date Title
US10493137B2 (en) Immune response inducer
CA2773083C (en) Immunity-inducing agent for prophylaxis or treatment of a pds5a-expressing cancer
DK2711017T3 (da) Immunitets-inducerende middel
US10537623B2 (en) Immunity induction agent
JP7160462B2 (ja) 免疫誘導剤
JP5504607B2 (ja) 免疫誘導剤
AU2014200551A1 (en) Immune Response Inducer